These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

668 related items for PubMed ID: 24989896

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Disease-modifying Antirheumatic Drugs (DMARD) and Combination Therapy of Conventional DMARD in Patients with Spondyloarthritis and Psoriatic Arthritis with Axial Involvement.
    Simone D, Nowik M, Gremese E, Ferraccioli GF.
    J Rheumatol Suppl; 2015 Nov; 93():65-9. PubMed ID: 26523061
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in real-world settings.
    Iannone F, Salaffi F, Fornaro M, Di Carlo M, Gentileschi S, Cantarini L, Lopalco G.
    Eur J Clin Invest; 2018 Nov; 48(11):e13013. PubMed ID: 30079593
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A Norwegian DMARD register: prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases.
    Kvien TK, Heiberg, Lie E, Kaufmann C, Mikkelsen K, Nordvåg BY, Rødevand E.
    Clin Exp Rheumatol; 2005 Nov; 23(5 Suppl 39):S188-94. PubMed ID: 16273806
    [Abstract] [Full Text] [Related]

  • 7. Pharmacologic treatment of psoriatic arthritis and axial spondyloarthritis with traditional biologic and non-biologic DMARDs.
    Soriano ER, Acosta-Felquer ML, Luong P, Caplan L.
    Best Pract Res Clin Rheumatol; 2014 Oct; 28(5):793-806. PubMed ID: 25488785
    [Abstract] [Full Text] [Related]

  • 8. Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study.
    Gibofsky A, Palmer WR, Goldman JA, Lautzenheiser RL, Markenson JA, Weaver A, Schiff MH, Keystone EC, Paulus HE, Harrison MJ, Whitmore JB, Leff JA.
    Curr Med Res Opin; 2006 Jan; 22(1):169-83. PubMed ID: 16393443
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Updated guidelines for the management of axial disease in psoriatic arthritis.
    Nash P, Lubrano E, Cauli A, Taylor WJ, Olivieri I, Gladman DD.
    J Rheumatol; 2014 Nov; 41(11):2286-9. PubMed ID: 25362712
    [Abstract] [Full Text] [Related]

  • 14. Adherence to biologic DMARD therapies in rheumatoid arthritis.
    Koncz T, Pentek M, Brodszky V, Ersek K, Orlewska E, Gulacsi L.
    Expert Opin Biol Ther; 2010 Sep; 10(9):1367-78. PubMed ID: 20681888
    [Abstract] [Full Text] [Related]

  • 15. Patterns in use and costs of conventional and biologic disease-modifying anti-rheumatic drugs in Australia.
    Donges E, Staatz CE, Benham H, Kubler P, Hollingworth SA.
    Clin Exp Rheumatol; 2017 Sep; 35(6):907-912. PubMed ID: 28421991
    [Abstract] [Full Text] [Related]

  • 16. Disease-modifying antirheumatic drug therapy for psoriatic arthritis.
    Salvarani C, Cantini F, Olivieri I.
    Clin Exp Rheumatol; 2002 Sep; 20(6 Suppl 28):S71-5. PubMed ID: 12463452
    [Abstract] [Full Text] [Related]

  • 17. Influenza vaccination status in rheumatoid arthritis and spondyloarthritis patients receiving biologic DMARDs.
    Michel M, Vincent FB, Rio S, Leon N, Marcelli C.
    Joint Bone Spine; 2016 Mar; 83(2):237-8. PubMed ID: 26190453
    [No Abstract] [Full Text] [Related]

  • 18. Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study.
    Gehin JE, Goll GL, Warren DJ, Syversen SW, Sexton J, Strand EK, Kvien TK, Bolstad N, Lie E.
    Arthritis Res Ther; 2019 Nov 29; 21(1):256. PubMed ID: 31783773
    [Abstract] [Full Text] [Related]

  • 19. Persistence of biological agents over an eight-year period in rheumatoid arthritis and spondyloarthritis patients.
    González-Fernández MÁ, Villamañán E, Jiménez-Nácher I, Moreno F, Herrero A, Balsa A.
    Farm Hosp; 2019 Jan 01; 43(1):24-30. PubMed ID: 30624170
    [Abstract] [Full Text] [Related]

  • 20. Identification of cutpoints for acceptable health status and important improvement in patient-reported outcomes, in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Kvamme MK, Kristiansen IS, Lie E, Kvien TK.
    J Rheumatol; 2010 Jan 01; 37(1):26-31. PubMed ID: 19955045
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.